Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Proteostasis Ther (PTI)

Proteostasis Ther (PTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 202,982
  • Shares Outstanding, K 51,129
  • Annual Sales, $ 2,840 K
  • Annual Income, $ -61,830 K
  • 60-Month Beta 0.34
  • Price/Sales 63.55
  • Price/Cash Flow N/A
  • Price/Book 2.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.31
  • Number of Estimates 1
  • High Estimate -0.31
  • Low Estimate -0.31
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +13.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.00 +326.00%
on 11/12/19
4.72 -9.75%
on 12/11/19
+3.27 (+330.30%)
since 11/11/19
3-Month
0.70 +508.57%
on 10/21/19
4.72 -9.75%
on 12/11/19
+3.34 (+363.35%)
since 09/11/19
52-Week
0.61 +598.36%
on 08/14/19
5.80 -26.55%
on 12/17/18
-0.67 (-13.59%)
since 12/11/18

Most Recent Stories

More News
Why Pharmaceutical R&D Global Spending Could Exceed $200 Billion by 2024

According to various industry and market publications, pharmaceutical companies spend, on average, 17% of revenues on R&D, making it one of the biggest spenders in this area. Outside of the semiconductor...

CNSP : 3.87 (+2.38%)
AGIO : 44.08 (-0.38%)
PTI : 4.26 (+7.30%)
LLY : 120.78 (+0.11%)
SGMO : 8.64 (-4.58%)
Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes Ineligible for Approved CFTR Modulators

Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced...

PTI : 4.26 (+7.30%)
Proteostasis Therapeutics, Inc. (PTI) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Proteostasis Therapeutics, Inc. (PTI).

PTI : 4.26 (+7.30%)
Proteostasis Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other...

PTI : 4.26 (+7.30%)
Proteostasis Therapeutics Regains Compliance with Nasdaq Listing Standards

Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases...

PTI : 4.26 (+7.30%)
Biotech Tops in November: Best ETFs & Stocks

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

CNCR : 23.03 (-0.96%)
BBC : 35.66 (-0.96%)
BBP : 42.90 (-1.59%)
GBT : 78.45 (+3.29%)
PTI : 4.26 (+7.30%)
VRTX : 220.00 (-0.12%)
CLVS : 11.72 (-3.14%)
MYOV : 15.94 (-1.60%)
CNST : 36.09 (+1.63%)
KRTX : 64.42 (-3.19%)
CRSP : 65.65 (-2.93%)
ARKG : 34.27 (-0.90%)
GNOM : 15.85 (-1.50%)
Are Options Traders Betting on a Big Move in Proteostasis Therapeutics (PTI) Stock?

Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.

PTI : 4.26 (+7.30%)
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

PTH : 90.45 (-0.23%)
PBE : 54.84 (-0.46%)
XBI : 94.27 (-1.32%)
CNCR : 23.03 (-0.96%)
DXCM : 212.36 (-1.47%)
CLVS : 11.72 (-3.14%)
BIIB : 292.23 (-1.67%)
PTI : 4.26 (+7.30%)
AQST : 7.70 (+2.53%)
FTSV : 35.96 (+3.77%)
ARKG : 34.27 (-0.90%)
Proteostasis: 3Q Earnings Snapshot

BOSTON (AP) _ Proteostasis Therapeutics Inc. (PTI) on Thursday reported a loss of $12.8 million in its third quarter.

PTI : 4.26 (+7.30%)
Proteostasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases...

PTI : 4.26 (+7.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade PTI with:

Business Summary

Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts....

See More

Key Turning Points

2nd Resistance Point 4.98
1st Resistance Point 4.62
Last Price 4.26
1st Support Level 4.00
2nd Support Level 3.75

See More

52-Week High 5.80
Last Price 4.26
Fibonacci 61.8% 3.82
Fibonacci 50% 3.21
Fibonacci 38.2% 2.59
52-Week Low 0.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar